Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xuebijing in AKI after high-voltage electrical burns
NCT07026227Completed
- Sponsor
- The First Hospital of Hebei Medical University
- Start
- Feb 2023
- Primary completion
- Aug 2023
- Modality
- PE (Plant Extract)
- Countries
- 1
01
Overview
Randomised, open-label trial of xuebijing in acute kidney injury (AKI), sponsored by The First Hospital of Hebei Medical University. Primary endpoints: Serum Creatinine at 7 days and Blood Urea Nitrogen at 7 days. Started Feb 2023; status: completed.
02
Drugs
xuebijing
03
Conditions
acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT07026227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07026227.